Andrew Reardon sold $1.0M of Ligand Pharmaceuticals Incorporated (LGND)

Executed May 1, disclosed May 4, 3 days later.

Value, as filed

$1.0M

4,532 sh across 5 lots

Executed

May 1

the trade date, as filed

Disclosed

May 4

3 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

Andrew Reardon CLO & Secretary profile →

Andrew Reardon (CLO & Secretary) filed 7 Form 4 reports in the trailing twelve months (0 purchases, 7 sales), most often in Ligand Pharmaceuticals Incorporated (LGND). The largest single filing was $1.5M of LGND (4,796 sh across 6 lots, as filed), executed Jul 1.

The name

LGND

Ligand Pharmaceuticals Incorporated LGND · Healthcare · 36 filings in 24 months ticker →

Healthcare · Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Andrew Reardon in LGND

LGNDSALE Ligand Pharmaceuticals Incorporated $1.3M
4,700 sh across 4 lots
Exec Sep 3
Filed Sep 8 · 6:34 PM ET LGNDSALE Ligand Pharmaceuticals Incorporated $1.3M
4,505 sh across 6 lots
Exec Aug 3
Filed Aug 4 · 6:42 PM ET LGNDSALE Ligand Pharmaceuticals Incorporated $1.5M
4,796 sh across 6 lots
Exec Jul 1
Filed Jul 6 · 5:11 PM ET LGNDSALE Ligand Pharmaceuticals Incorporated $999K
4,400 sh across 5 lots
Exec Jun 1
Filed Jun 2 · 5:30 PM ET LGNDSALE Ligand Pharmaceuticals Incorporated $846K
4,203 sh across 4 lots
Exec Apr 1
Filed Apr 2 · 5:30 PM ET LGNDSALE Ligand Pharmaceuticals Incorporated $666K
3,200 sh across 3 lots
Exec Mar 4
Filed Mar 6 · 5:30 PM ET LGNDSALE Ligand Pharmaceuticals Incorporated $104K
1,000 sh × $104.00
Exec May 15 2025
Filed Jun 2 2025 · 5:30 PM ET † LGNDSALE Ligand Pharmaceuticals Incorporated $199K
2,000 sh × $99.60
Exec Sep 23 2024
Filed Sep 25 2024 · 5:30 PM ET